BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Geschlossen

BrancheGesundheitswesen

92.54 -0.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

92.18

Max

94.26

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.3B

499M

Verkäufe

-6.5B

7.6B

KGV

Branchendurchschnitt

20.663

57.333

EPS

1.31

Dividendenrendite

4.32

Gewinnspanne

6.539

Angestellte

82,878

EBITDA

-3.7B

563M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+22.28% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.32%

2.63%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-20B

111B

Vorheriger Eröffnungskurs

93.42

Vorheriger Schlusskurs

92.54

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Apr. 2025, 08:52 UTC

Ergebnisse

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24. Apr. 2025, 05:44 UTC

Ergebnisse

Sanofi Sales, Profit Beat Expectations

9. Apr. 2025, 06:00 UTC

Akquisitionen, Fusionen, Übernahmen

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20. März 2025, 06:43 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24. Apr. 2025, 12:54 UTC

Market Talk
Ergebnisse

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24. Apr. 2025, 10:06 UTC

Market Talk
Ergebnisse

Sanofi Starts the Year Strong -- Market Talk

10. Apr. 2025, 12:06 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10. Apr. 2025, 09:10 UTC

Heiße Aktien

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9. Apr. 2025, 10:49 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9. Apr. 2025, 08:19 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9. Apr. 2025, 06:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9. Apr. 2025, 06:46 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4. Apr. 2025, 09:07 UTC

Heiße Aktien

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3. Apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2. Apr. 2025, 13:44 UTC

Market Talk

Santander Push Into Canada on the Cards -- Market Talk

2. Apr. 2025, 09:27 UTC

Heiße Aktien

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26. März 2025, 06:19 UTC

Market Talk
Ergebnisse

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25. März 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20. März 2025, 09:00 UTC

Top News

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20. März 2025, 06:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20. März 2025, 06:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20. März 2025, 06:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Pay $600M Upfront

20. März 2025, 06:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20. März 2025, 06:00 UTC

Akquisitionen, Fusionen, Übernahmen

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18. März 2025, 09:33 UTC

Heiße Aktien

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17. März 2025, 23:00 UTC

Top News

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13. März 2025, 09:50 UTC

Ergebnisse

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13. März 2025, 09:49 UTC

Ergebnisse

Santander Increased 2024 Cash Payments by 19%

24. Feb. 2025, 08:56 UTC

Market Talk
Ergebnisse

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24. Feb. 2025, 08:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

22.28% Vorteil

12-Monats-Prognose

Durchschnitt 114.144 EUR  22.28%

Hoch 127 EUR

Tief 83.729 EUR

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

10

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

91.62 / 93.4Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.